NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 6, 2004 • Volume 1 / Number 14 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Chemoprevention Study of Selenium for Non-Small Cell Lung Cancer

Name of the Trial
Phase III Randomized Chemoprevention Study of Selenium in Participants with Previously Resected Stage I Non-Small Cell Lung Cancer (ECOG-5597). See the protocol summary at http://cancer.gov/clinicaltrials/ECOG-5597.

Dr. Daniel David KarpPrincipal Investigators
Dr. Daniel David Karp, Eastern Cooperative Oncology Group; Dr. Michael Liptay, American College of Surgeons Oncology Group; Dr. Omer Kucuk, Southwest Oncology Group; Dr. Randolph Marks, North Central Cancer Treatment Group; Dr. Michael R. Johnston, National Cancer Institute of Canada; Dr. Gerald H. Clamon, Cancer and Leukemia Group B; Dr. Steven Belinsky, Lovelace Respiratory Research Institute

Why Is This Trial Important?
Lung cancer kills more Americans than any other cancer. Surgical removal of tumors is the preferred treatment for non-small cell lung cancer. However, the incidence of a second tumor developing in patients who have been treated surgically for early-stage non-small cell lung cancer is about 20-30 percent.

Researchers are investigating selenium as a chemoprevention agent against development of secondary lung tumors. "With stage 1 non-small cell lung cancers that have been treated successfully with surgery, the more likely risk is development of a second tumor rather than recurrence of the original tumor," said Dr. Karp. "So we are interested in seeing if selenium will be effective in preventing the growth of new tumors in patients who have undergone curative surgery for non-small cell lung cancer."

In a previous study, selenium appeared to cause decreases in both prostate and lung cancer, but those results were not statistically validated. Subsequent studies, including this one, seek to validate those observations," Dr. Karp said.

Who Can Join This Trial?
Researchers seek to enroll 1,960 patients 18 years of age and older who have had stage I non-small cell lung cancer completely removed by surgery. See the full list of eligibility criteria for this trial at http://cancer.gov/clinicaltrials/ECOG-5597.

Where Is This Trial Taking Place?
Study sites in the United States and elsewhere are enrolling patients in this trial. See the list of study sites at http://cancer.gov/clinicaltrials/ECOG-5597.

Who to Contact
See the list of study contacts at http://cancer.gov/clinicaltrials/ECOG-5597 or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.


An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.